☰

Stefan Lorenzl, MD - Publications

Affiliations: 
Neurology Ludwig-Maximilians-Universität München, München, Bayern, Germany 
Tree Info Grants Similar researchers PubMed Report error

16 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2012 Nübling G, Levin J, Bader B, Israel L, Bötzel K, Lorenzl S, Giese A. Limited cleavage of tau with matrix-metalloproteinase MMP-9, but not MMP-3, enhances tau oligomer formation. Experimental Neurology. 237: 470-6. PMID 22890115 DOI: 10.1016/j.expneurol.2012.07.018  0.517
2009 Levin J, Giese A, Boetzel K, Israel L, Högen T, Nübling G, Kretzschmar H, Lorenzl S. Increased alpha-synuclein aggregation following limited cleavage by certain matrix metalloproteinases. Experimental Neurology. 215: 201-8. PMID 19022250 DOI: 10.1016/j.expneurol.2008.10.010  0.399
2008 Lorenzl S, Buerger K, Hampel H, Beal MF. Profiles of matrix metalloproteinases and their inhibitors in plasma of patients with dementia. International Psychogeriatrics / Ipa. 20: 67-76. PMID 17697439 DOI: 10.1017/S1041610207005790  0.68
2007 Glas M, Popp B, Angele B, Koedel U, Chahli C, Schmalix WA, Anneser JM, Pfister HW, Lorenzl S. A role for the urokinase-type plasminogen activator system in amyotrophic lateral sclerosis. Experimental Neurology. 207: 350-6. PMID 17716658 DOI: 10.1016/j.expneurol.2007.07.007  0.46
2007 Kiaei M, Kipiani K, Calingasan NY, Wille E, Chen J, Heissig B, Rafii S, Lorenzl S, Beal MF. Matrix metalloproteinase-9 regulates TNF-alpha and FasL expression in neuronal, glial cells and its absence extends life in a transgenic mouse model of amyotrophic lateral sclerosis. Experimental Neurology. 205: 74-81. PMID 17362932 DOI: 10.1016/J.Expneurol.2007.01.036  0.77
2007 Kim YS, Choi DH, Block ML, Lorenzl S, Yang L, Kim YJ, Sugama S, Cho BP, Hwang O, Browne SE, Kim SY, Hong JS, Beal MF, Joh TH. A pivotal role of matrix metalloproteinase-3 activity in dopaminergic neuronal degeneration via microglial activation. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 21: 179-87. PMID 17116747 DOI: 10.1096/Fj.06-5865Com  0.745
2006 Lorenzl S, Narr S, Angele B, Krell HW, Gregorio J, Kiaei M, Pfister HW, Beal MF. The matrix metalloproteinases inhibitor Ro 28-2653 [correction of Ro 26-2853] extends survival in transgenic ALS mice. Experimental Neurology. 200: 166-71. PMID 16516196 DOI: 10.1016/J.Expneurol.2006.01.026  0.725
2004 Lorenzl S, Calingasan N, Yang L, Albers DS, Shugama S, Gregorio J, Krell HW, Chirichigno J, Joh T, Beal MF. Matrix metalloproteinase-9 is elevated in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice. Neuromolecular Medicine. 5: 119-32. PMID 15075439 DOI: 10.1385/Nmm:5:2:119  0.79
2004 Lorenzl S, Albers DS, Chirichigno JW, Augood SJ, Beal MF. Elevated levels of matrix metalloproteinases-9 and -1 and of tissue inhibitors of MMPs, TIMP-1 and TIMP-2 in postmortem brain tissue of progressive supranuclear palsy. Journal of the Neurological Sciences. 218: 39-45. PMID 14759631 DOI: 10.1016/J.Jns.2003.10.015  0.676
2003 Yang L, Sugama S, Chirichigno JW, Gregorio J, Lorenzl S, Shin DH, Browne SE, Shimizu Y, Joh TH, Beal MF, Albers DS. Minocycline enhances MPTP toxicity to dopaminergic neurons. Journal of Neuroscience Research. 74: 278-85. PMID 14515357 DOI: 10.1002/Jnr.10709  0.685
2003 Lorenzl S, De Pasquale G, Segal AZ, Beal MF. Dysregulation of the levels of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in the early phase of cerebral ischemia. Stroke; a Journal of Cerebral Circulation. 34: e37-8; author reply . PMID 12750528 DOI: 10.1161/01.Str.0000075563.45920.24  0.685
2003 Lorenzl S, Albers DS, Relkin N, Ngyuen T, Hilgenberg SL, Chirichigno J, Cudkowicz ME, Beal MF. Increased plasma levels of matrix metalloproteinase-9 in patients with Alzheimer's disease. Neurochemistry International. 43: 191-6. PMID 12689599 DOI: 10.1016/S0197-0186(03)00004-4  0.71
2003 Lorenzl S, Albers DS, LeWitt PA, Chirichigno JW, Hilgenberg SL, Cudkowicz ME, Beal MF. Tissue inhibitors of matrix metalloproteinases are elevated in cerebrospinal fluid of neurodegenerative diseases. Journal of the Neurological Sciences. 207: 71-6. PMID 12614934 DOI: 10.1016/S0022-510X(02)00398-2  0.671
2003 Sugama S, Yang L, Cho BP, DeGiorgio LA, Lorenzl S, Albers DS, Beal MF, Volpe BT, Joh TH. Age-related microglial activation in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurodegeneration in C57BL/6 mice. Brain Research. 964: 288-94. PMID 12576189 DOI: 10.1016/S0006-8993(02)04085-4  0.617
2002 Lorenzl S, Albers DS, Narr S, Chirichigno J, Beal MF. Expression of MMP-2, MMP-9, and MMP-1 and their endogenous counterregulators TIMP-1 and TIMP-2 in postmortem brain tissue of Parkinson's disease. Experimental Neurology. 178: 13-20. PMID 12460604 DOI: 10.1006/Exnr.2002.8019  0.728
1998 Paul R, Lorenzl S, Koedel U, Sporer B, Vogel U, Frosch M, Pfister HW. Matrix metalloproteinases contribute to the blood-brain barrier disruption during bacterial meningitis. Annals of Neurology. 44: 592-600. PMID 9778257 DOI: 10.1002/ana.410440404  0.468
Show low-probability matches.